Plain-English translation of NCT05795335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study is tracking how well CDK4/6 inhibitors work for people with advanced hormone receptor-positive breast cancer that has spread or come back. Researchers want to understand which patients benefit most from this medication, what side effects people experience, and whether certain blood or tumor markers can predict who will respond best to treatment.
Even though this medication is already being used to treat advanced breast cancer, doctors need to better understand which patients will benefit most from it, how long people survive on the treatment, and which side effects are most common. This information will help doctors personalize treatment decisions and prepare patients for what to expect.
You likely qualify if…
You likely don't qualify if…
You would be enrolled in the study either as you begin the medication or if you are already taking it. Researchers would track your progress over time, collecting information about how the treatment is working, any side effects you experience, and samples for blood work or biomarker testing. The study takes place at a single hospital center and involves regular follow-up visits and monitoring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Sponsor
RenJi Hospital
Enrollment target
~172 participants
Started
April 2023
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ziping Wu, MD
RenJi Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.